| Dr Mohamad H Alsabban, MD | |
|
133 Route 3, Dededo, GU 96929-6911 | |
| (671) 645-5500 | |
| Not Available |
| Full Name | Dr Mohamad H Alsabban |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 44 Years |
| Location | 133 Route 3, Dededo, Guam |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1942226790 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZC0500X | Pathology - Cytopathology | 036074588 (Illinois) | Secondary |
| 207ZC0500X | Pathology - Cytopathology | M-1765 (Guam) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Guam Regional Medical City | Dededo, GU | Hospital |
| Guam Memorial Hospital Authority | Tamuning, GU | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Guam Healthcare Development Incorporated | 9234351776 | 124 |
| Guam Memorial Hospital | 5890781694 | 56 |
News Archive
At age two, children who were born with neurological abnormalities due to congenital Zika Virus (ZIKV) have a range of neurodevelopmental profiles that can be tracked using a routine neurological assessment, according to a new study published this week in the open-access journal PLOS ONE by Dr. Albert Ko of Yale University, US and Dr. Federico Costa of The Federal University of Bahia, Brazil, and their colleagues.
Valocor Therapeutics, Inc., a newly formed company focused on the development of innovative therapies for the treatment of dermatologic conditions, today announced the acquisition and license of certain dermatology therapeutic programs from QLT Inc.. This transaction was facilitated by a seed financing for Valocor led by the Working Opportunity Fund, which is managed by GrowthWorks Capital Ltd.
The International Agency for Research on Cancer (IARC), the specialized cancer agency of the World Health Organization, today celebrates the 50th anniversary of its establishment with the launch of the book International Agency for Research on Cancer: The First 50 Years, 1965–2015.
During the dog days of summer, when temperatures are holding steady around 90 degrees, it can be easy to let your children sit in front of the television while enjoying the cool of the air conditioning.
ProUroCare Medical, Inc. today announced the completion of a National Institute of Health and National Cancer Institute-supported clinical study. The study's purpose was to evaluate the ability of the company's ProUroScan imaging system to visualize and document abnormalities in the prostate detected or monitored by the digital rectal exam (DRE).
› Verified 6 days ago
| Entity Name | Guam Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366519027 PECOS PAC ID: 5890781694 Enrollment ID: O20040426000038 |
News Archive
At age two, children who were born with neurological abnormalities due to congenital Zika Virus (ZIKV) have a range of neurodevelopmental profiles that can be tracked using a routine neurological assessment, according to a new study published this week in the open-access journal PLOS ONE by Dr. Albert Ko of Yale University, US and Dr. Federico Costa of The Federal University of Bahia, Brazil, and their colleagues.
Valocor Therapeutics, Inc., a newly formed company focused on the development of innovative therapies for the treatment of dermatologic conditions, today announced the acquisition and license of certain dermatology therapeutic programs from QLT Inc.. This transaction was facilitated by a seed financing for Valocor led by the Working Opportunity Fund, which is managed by GrowthWorks Capital Ltd.
The International Agency for Research on Cancer (IARC), the specialized cancer agency of the World Health Organization, today celebrates the 50th anniversary of its establishment with the launch of the book International Agency for Research on Cancer: The First 50 Years, 1965–2015.
During the dog days of summer, when temperatures are holding steady around 90 degrees, it can be easy to let your children sit in front of the television while enjoying the cool of the air conditioning.
ProUroCare Medical, Inc. today announced the completion of a National Institute of Health and National Cancer Institute-supported clinical study. The study's purpose was to evaluate the ability of the company's ProUroScan imaging system to visualize and document abnormalities in the prostate detected or monitored by the digital rectal exam (DRE).
› Verified 6 days ago
| Entity Name | Guam Healthcare Development Incorporated |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326447939 PECOS PAC ID: 9234351776 Enrollment ID: O20150326000266 |
News Archive
At age two, children who were born with neurological abnormalities due to congenital Zika Virus (ZIKV) have a range of neurodevelopmental profiles that can be tracked using a routine neurological assessment, according to a new study published this week in the open-access journal PLOS ONE by Dr. Albert Ko of Yale University, US and Dr. Federico Costa of The Federal University of Bahia, Brazil, and their colleagues.
Valocor Therapeutics, Inc., a newly formed company focused on the development of innovative therapies for the treatment of dermatologic conditions, today announced the acquisition and license of certain dermatology therapeutic programs from QLT Inc.. This transaction was facilitated by a seed financing for Valocor led by the Working Opportunity Fund, which is managed by GrowthWorks Capital Ltd.
The International Agency for Research on Cancer (IARC), the specialized cancer agency of the World Health Organization, today celebrates the 50th anniversary of its establishment with the launch of the book International Agency for Research on Cancer: The First 50 Years, 1965–2015.
During the dog days of summer, when temperatures are holding steady around 90 degrees, it can be easy to let your children sit in front of the television while enjoying the cool of the air conditioning.
ProUroCare Medical, Inc. today announced the completion of a National Institute of Health and National Cancer Institute-supported clinical study. The study's purpose was to evaluate the ability of the company's ProUroScan imaging system to visualize and document abnormalities in the prostate detected or monitored by the digital rectal exam (DRE).
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mohamad H Alsabban, MD Po Box 24905, Barrigada, GU 96921-4905 Ph: (671) 787-1894 | Dr Mohamad H Alsabban, MD 133 Route 3, Dededo, GU 96929-6911 Ph: (671) 645-5500 |
News Archive
At age two, children who were born with neurological abnormalities due to congenital Zika Virus (ZIKV) have a range of neurodevelopmental profiles that can be tracked using a routine neurological assessment, according to a new study published this week in the open-access journal PLOS ONE by Dr. Albert Ko of Yale University, US and Dr. Federico Costa of The Federal University of Bahia, Brazil, and their colleagues.
Valocor Therapeutics, Inc., a newly formed company focused on the development of innovative therapies for the treatment of dermatologic conditions, today announced the acquisition and license of certain dermatology therapeutic programs from QLT Inc.. This transaction was facilitated by a seed financing for Valocor led by the Working Opportunity Fund, which is managed by GrowthWorks Capital Ltd.
The International Agency for Research on Cancer (IARC), the specialized cancer agency of the World Health Organization, today celebrates the 50th anniversary of its establishment with the launch of the book International Agency for Research on Cancer: The First 50 Years, 1965–2015.
During the dog days of summer, when temperatures are holding steady around 90 degrees, it can be easy to let your children sit in front of the television while enjoying the cool of the air conditioning.
ProUroCare Medical, Inc. today announced the completion of a National Institute of Health and National Cancer Institute-supported clinical study. The study's purpose was to evaluate the ability of the company's ProUroScan imaging system to visualize and document abnormalities in the prostate detected or monitored by the digital rectal exam (DRE).
› Verified 6 days ago